ProCE Banner Activity

TRANSFORM-1: Phase III Trial of Navitoclax + Ruxolitinib vs Placebo + Ruxolitinib in Previously Untreated Myelofibrosis

Conference Coverage

TRANSFORM-1 met its primary endpoint, demonstrating a significantly improved SVR35 at Week 24 with navitoclax plus ruxolitinib vs placebo plus ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Released: December 12, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.